SARS-CoV-2 vaccine uptake and risks of severe COVID-19 disease among people prescribed opioid agonist therapy in Scotland

Alan Yeung, Max Wilkinson, Jen Bishop, Bob Taylor, Norah Palmateer, Lee Barnsdale, Jaroslaw Lang, Claire Cameron, Duncan McCormick, Tracey Clusker, Andrew McAuley, Sharon Hutchinson
{"title":"SARS-CoV-2 vaccine uptake and risks of severe COVID-19 disease among people prescribed opioid agonist therapy in Scotland","authors":"Alan Yeung, Max Wilkinson, Jen Bishop, Bob Taylor, Norah Palmateer, Lee Barnsdale, Jaroslaw Lang, Claire Cameron, Duncan McCormick, Tracey Clusker, Andrew McAuley, Sharon Hutchinson","doi":"10.1136/jech-2023-221602","DOIUrl":null,"url":null,"abstract":"Background There is limited evidence quantifying the risk of severe COVID-19 disease among people with opioid dependence. We examined vaccine uptake and severe disease (admission to critical care or death with COVID-19) among individuals prescribed opioid agonist therapy (OAT). Method A case–control design was used to examine vaccine uptake in those prescribed OAT compared with the general population, and the association between severe disease and OAT. In both analyses, 10 controls from the general population were matched (to each OAT recipient and COVID-19 case, respectively) according to socio-demographic factors. Conditional logistic regression was used to estimate rate ratios (RR) for severe disease. Results Vaccine uptake was markedly lower in the OAT cohort (dose 1: 67%, dose 2: 53% and dose 3: 31%) compared with matched controls (76%, 72% and 57%, respectively). Those prescribed OAT within the last 5 years, compared with those not prescribed, had increased risk of severe COVID-19 (RR 3.38, 95% CI 2.75 to 4.15), particularly in the fourth wave (RR 6.58, 95% CI 4.20 to 10.32); adjustment for comorbidity and vaccine status attenuated this risk (adjusted RR (aRR) 2.43, 95% CI 1.95 to 3.02; wave 4 aRR 3.78, 95% CI 2.30 to 6.20). Increased risk was also observed for those prescribed OAT previously (>3 months ago) compared with recently (aRR 1.74, 95% CI 1.11 to 2.71). Conclusions The widening gap in vaccine coverage for those prescribed OAT, compared with the general population, is likely to have exacerbated the risk of severe COVID-19 in this population over the pandemic. However, continued OAT use may have provided protection from severe COVID-19 among those with opioid dependence. Data may be obtained from a third party and are not publicly available. Access to the individual level data can be sought through approval of the Public Benefit and Privacy Panel for Health and Social Care ([www.informationgovernance.scot.nhs.uk/pbpphsc/home/for-applicants/][1]). [1]: http://www.informationgovernance.scot.nhs.uk/pbpphsc/home/for-applicants/","PeriodicalId":15778,"journal":{"name":"Journal of Epidemiology & Community Health","volume":"46 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Epidemiology & Community Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/jech-2023-221602","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background There is limited evidence quantifying the risk of severe COVID-19 disease among people with opioid dependence. We examined vaccine uptake and severe disease (admission to critical care or death with COVID-19) among individuals prescribed opioid agonist therapy (OAT). Method A case–control design was used to examine vaccine uptake in those prescribed OAT compared with the general population, and the association between severe disease and OAT. In both analyses, 10 controls from the general population were matched (to each OAT recipient and COVID-19 case, respectively) according to socio-demographic factors. Conditional logistic regression was used to estimate rate ratios (RR) for severe disease. Results Vaccine uptake was markedly lower in the OAT cohort (dose 1: 67%, dose 2: 53% and dose 3: 31%) compared with matched controls (76%, 72% and 57%, respectively). Those prescribed OAT within the last 5 years, compared with those not prescribed, had increased risk of severe COVID-19 (RR 3.38, 95% CI 2.75 to 4.15), particularly in the fourth wave (RR 6.58, 95% CI 4.20 to 10.32); adjustment for comorbidity and vaccine status attenuated this risk (adjusted RR (aRR) 2.43, 95% CI 1.95 to 3.02; wave 4 aRR 3.78, 95% CI 2.30 to 6.20). Increased risk was also observed for those prescribed OAT previously (>3 months ago) compared with recently (aRR 1.74, 95% CI 1.11 to 2.71). Conclusions The widening gap in vaccine coverage for those prescribed OAT, compared with the general population, is likely to have exacerbated the risk of severe COVID-19 in this population over the pandemic. However, continued OAT use may have provided protection from severe COVID-19 among those with opioid dependence. Data may be obtained from a third party and are not publicly available. Access to the individual level data can be sought through approval of the Public Benefit and Privacy Panel for Health and Social Care ([www.informationgovernance.scot.nhs.uk/pbpphsc/home/for-applicants/][1]). [1]: http://www.informationgovernance.scot.nhs.uk/pbpphsc/home/for-applicants/
苏格兰接受阿片类受体激动剂治疗者的 SARS-CoV-2 疫苗接种率和严重 COVID-19 疾病风险
背景 对阿片类药物依赖者患严重 COVID-19 疾病的风险进行量化的证据有限。我们研究了阿片类药物激动剂疗法(OAT)处方者的疫苗接种率和严重疾病(因 COVID-19 而入院接受重症监护或死亡)发生率。方法 我们采用了病例对照设计来研究与普通人群相比,OAT处方者的疫苗接种率,以及严重疾病与OAT之间的关联。在这两项分析中,根据社会人口因素从普通人群中挑选了 10 名对照组(分别与 OAT 接种者和 COVID-19 病例匹配)。条件逻辑回归用于估计严重疾病的比率(RR)。结果 与匹配对照组(分别为 76%、72% 和 57%)相比,OAT 组群的疫苗接种率明显较低(第一剂:67%;第二剂:53%;第三剂:31%)。与未服用 OAT 的人群相比,在过去 5 年中服用过 OAT 的人群发生严重 COVID-19 的风险增加(RR 3.38,95% CI 2.75 至 4.15),尤其是在第四波(RR 6.58,95% CI 4.20 至 10.32);对合并症和疫苗接种状况进行调整后,这一风险有所降低(调整后 RR (aRR) 2.43,95% CI 1.95 至 3.02;第四波 aRR 3.78,95% CI 2.30 至 6.20)。以前(>3 个月前)开过 OAT 处方的人与最近开过 OAT 处方的人相比,风险也有所增加(aRR 1.74,95% CI 1.11 至 2.71)。结论 与普通人群相比,开具 OAT 的人群在疫苗覆盖率方面的差距不断扩大,这很可能加剧了这一人群在大流行期间罹患严重 COVID-19 的风险。不过,继续使用 OAT 可能会保护阿片类药物依赖者免受严重 COVID-19 的感染。数据可能来自第三方,不对外公开。个人层面的数据可通过卫生与社会保健公共利益与隐私小组([www.informationgovernance.scot.nhs.uk/pbpphsc/home/for-applicants/][1])的批准获取。[1]: http://www.informationgovernance.scot.nhs.uk/pbpphsc/home/for-applicants/
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信